Abstracts tagged "Enthesitis"

Abstract Number: 0149 • ACR Convergence 2021
Development of Joint Effusion, Hyperperfusion and Enthesitis After One Hour of Age-and Gender Adjusted Weight Training
Julia Schreiner¹, Dennis Scheicht², Pantelis Karakostas³, Jana Ziob¹, Charlotte Behning¹, Peter Preuss⁴, Peter Brossart⁵ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²Porz am Rhein Hospital, Cologne, Germany, ³Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ⁴University of Bonn, Bonn, Germany, ⁵Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany
Background/Purpose: Ultrasound is an established tool to detect changes of joints, tendons and entheses in rheumatology. However, several studies detected structural and vascular changes in…
Abstract Number: 1340 • ACR Convergence 2021
Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)
Fabrizio Cantini¹, Antonio Marchesoni², Francesca Marando³, Giuliana Gualberti³, Lucia Novelli³, Giacomo Curradi³, Erin McDearmon-Blondell⁴, Tianming Gao⁵ and Carlo Salvarani⁶, ¹Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy, ²Dipartimento di Reumatologia, ASST Gaetano Pini-CTO, Milano, Italy, ³AbbVie, Rome, Italy, ⁴AbbVie Inc., Elmhurst, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Reaching control or improvement on enthesitis domain in psoriatic arthritis (PsA) is challenging, and it continues to be a priority for patients (pts) and…
Abstract Number: 1797 • ACR Convergence 2021
Are Smoking and Alcohol Associated with Peripheral Musculoskeletal Involvement in Patients with Spondyloarthritis? Results from the ASAS-PerSpA Study
M.Lourdes Ladehesa-Pineda¹, Rafaela Ortega², Mara ngeles Puche Larrubia¹, Maxime Dougados³, Eduardo Collantes-Estevez² and Clementina López Medina⁴, ¹Hospital Universitario Reina Sofía, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: There are controversies around the role of smoking in manifestations of axial spondyloarthritis (axSpA) such as peripheral involvement. It has been observed an inverse…
Abstract Number: 1829 • ACR Convergence 2021
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Rita Torres¹, Santiago Manica² and Fernando Santos², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 287 • 2019 ACR/ARP Annual Meeting
Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review
Nancy Desai¹, Justin Bucci ¹ and Eugene Kissin ², ¹Boston Medical Center, Boston, ²Boston University, Boston, MA
Background/Purpose: Ultrasound (US) evaluation of the Achilles tendon has been utilized to assess involvement at the entheses in the setting various inflammatory, metabolic and mechanical…
Abstract Number: 1482 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett¹, Xenofon Baraliakos ², Filip Van den Bosch ³, Atul Deodhar ⁴, Lianne Gensler ⁵, Mikkel Østergaard ⁶, Shital Agawane ⁷, Ayan Das Gupta ⁷, Shephard Mpofu ⁸, Todd Fox ⁸, Adam Winseck ⁹, Brian Porter ⁹ and Abhijit Shete ⁸, ¹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Oregon Health & Science University, Portland, OR, ⁵University San Francisco California, San Francisco, CA, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…
Abstract Number: 1493 • 2019 ACR/ARP Annual Meeting
Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Joseph Merola¹, Aubrey Trevelin Sprabery ², Amanda Gellett ², Chen-Yen Lin ² and Dennis McGonagle ³, ¹Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Multiple biologic DMARD (bDMARD) treatments are available for PsA, but there is limited research that compares the safety and efficacy of these treatments. Head-to-head…
Abstract Number: 1778 • 2019 ACR/ARP Annual Meeting
Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis
Sungsin Jo¹, Young Lim Lee ¹, Tae-Han Lee ¹, Ye-Soo Park ² and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Department of Orthopedic Surgery, Hanyang University Medical Center, Guri Hospital,, Guri, Republic of Korea
Background/Purpose: Enthesitis is characterized by inflammation at the interface where tendon or ligament attaches to the bone and is a representative symptom of ankylosing spondylitis(AS).…
Abstract Number: 2455 • 2019 ACR/ARP Annual Meeting
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Ana-Maria Orbai¹, Birt Julie ², Elizabeth Holdsworth ³, Nicola Booth ⁴, Matthew M. Hufford ², Malatestinic William ², Aubrey Trevelin Sprabery ² and Anthony Reginato ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Division of Rheumatology, Providence VAMC, Associate Professor in Medicine, The Warren Alpert School of Medicine, Providence
Background/Purpose: Enthesitis, a characteristic clinical feature of psoriatic arthritis (PsA) [1], is a core outcome for PsA clinical trials. While enthesitis is considered important when…
Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens¹, Philipp Sewerin ², Eugenio de Miguel ³, Yusuf Patel ⁴, Anastas Batalov ⁵, Eva Dokoupilova ⁶, Christine Kleinmond ⁷, Effie Pournara ⁸, Ankita Shekhawat ⁹, Claudia Jentzsch ¹⁰, Annette Wiedon ¹⁰ and Xenofon Baraliakos ¹¹, ¹CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…
Abstract Number: 2065 • 2018 ACR/ARHP Annual Meeting
Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis
Yukiko Maeda¹, Zheni Stavre¹, Tingting Huang², Catherine Manning², Bryant Shaughn³, Michael Macoritto³, Deborah Hyland³, Wendy Waegell³ and Ellen M. Gravallese⁴, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, worcester, MA, ³Abbvie Bioresearch Center, worcester, MA, ⁴Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) results in significant pain and loss of function due to inflammation and resulting enthesial/periosteal bone formation. Inhibition of the Janus kinase (JAK)/STAT…
Abstract Number: 2398 • 2018 ACR/ARHP Annual Meeting
Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category
Dax G. Rumsey¹, Jaime Guzman², Alan Rosenberg³, Adam Huber⁴, Rosie Scuccimarri⁵, Natalie J. Shiff⁶, Alessandra Bruns⁷, Brian M. Feldman⁸ and Dean Eurich⁹, ¹Paediatrics, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ³Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, ⁶University of Florida, Gainesville, FL, ⁷Hospitalier de l’Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada
Background/Purpose: To estimate the impact of enthesitis on patient reported outcomes (PROs) in children with juvenile idiopathic arthritis (JIA), irrespective of their JIA category. Methods:…
Abstract Number: 2826 • 2018 ACR/ARHP Annual Meeting
Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedolizumab Therapy for Inflammatory Bowel Disease
Sayam Dubash^1,2, Marianayagam Thiraupathy³, Ilaria Tinazzi⁴, Tariq Al Araimi⁵, Christian Pagnoux⁶, Adam Weizman⁷, Pascal Richette^8,9, My-Linh Tran Minh¹⁰, Mattieu Allez¹⁰, Animesh Singh¹¹, Francesco Ciccia¹², John Hamlin¹³, Ai Lyn Tan^1,2, Helena Marzo-Ortega^1,2 and Dennis McGonagle^1,2, ¹Rheumatology, Chapel Allerton Hospital, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³East and North Hertfordshire NHS Trust, Stevenage, United Kingdom, ⁴Rheumatology, Sacro Cuore-Don Calabria Hospital, Negrar, Italy, ⁵Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁷Gastroenterology, Mount Sinai Hospital, Toronto, ON, Canada, ⁸Rheumatology, Université Paris Diderot, Paris, France, ⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁰Department of Gastroenterology, APHP, Hôpital Saint Louis, Sorbonne Paris-Cité University, Paris, France, ¹¹Rheumatology, The Royal Free Hospital, London, United Kingdom, ¹²Rheumatology, University of Palermo, Palermo, Italy, ¹³Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Vedolizumab therapy for inflammatory bowel disease (IBD) has been associated with mild spondyloarthritis (SpA) related features including sacroiliitis and synovitis. Herein, we report a…
Abstract Number: 2886 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
Laura C. Coates¹, Dennis McGonagle², Georg Schett³, Philip J. Mease⁴, Erhard Quebe-Fehling⁵, D. L. Asquith⁶, L. Rasouliyan⁷, Shephard Mpofu⁵ and Corine Gaillez⁵, ¹University of Oxford, Oxford, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Swedish Medical Centre and University of Washington, Seattle, WA, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals UK Ltd, Camberley, United Kingdom, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralizes IL-17A, provided significant and sustained improvement in the signs and symptoms of active PsA,…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].